Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes - Research and Markets

Research and Markets
Posted on: 14 Nov 17

The "Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes" report has been added to Research and Markets' offering.

Global Diabetes Drugs Market to 2023 comprehensively reviews the strategies of key players in the DM market, and provides market share forecasts. Pipeline and marketed products are analyzed in detail, along with the impact that products expected to come to market between 2016 and 2023 will have on existing established products. Licensing and co-marketing deals in DM are analyzed by region and value.

The DM market has undergone a dynamic shift over the past decade, primarily due to the entry of three new non-insulin drug classes for T2DM: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose linked transporter 2 (SGLT-2) inhibitors. Increased market diversification is expected to continue throughout the forecast period due to patent expiries for major insulin products and increased uptake of non-insulin drugs.

Incidence of diabetes mellitus (DM), and most notably type 2 diabetes mellitus (T2DM), which accounts for more than 90% of all DM cases, is growing rapidly on a global scale. The US is expected to experience the greatest rise in T2DM prevalence, and incidence rates are also expected to increase to about 4% by 2023. Several factors are driving the increase of T2DM, with aging population and the prevalence of highly calorific diets being some of the key drivers.

In 2016, the top five products, all of which are insulin products, commanded almost half of the market by sales. By 2023, the top 10 products are expected to occupy more than 40% of the market share, many of which will be non-insulin products.

Competition will intensify over the forecast period as more companies enter the DM market space. However, Novo Nordisk, which is currently the leading player in terms of market share, is expected to maintain its position throughout the forecast period. Despite declining revenues for high-grossing products such as Levemir (insulin detemir), more recent market additions such as Tresiba (insulin degludec), as well as the upcoming pipeline products such as semaglutide and oral semaglutide are expected to more than compensate.

Key Topics Covered:

1. List of Tables & Figures

2 Introduction

3 Key Marketed Products

4 Pipeline Landscape Assessment

5 Multi-scenario Market Forecast to 2023

6 Company Analysis and Positioning

7 Strategic Consolidations

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/d8hv6n/global_diabetes

View source version on businesswire.com: http://www.businesswire.com/news/home/20171114006219/en/

Business Wire
www.businesswire.com

Last updated on: 14/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.